These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34389432)

  • 1. A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis.
    Wang T; Liu Z; She Y; Deng J; Zhong Y; Zhao M; Li S; Xie D; Sun X; Hu X; Chen C
    Cancer Lett; 2021 Nov; 520():321-331. PubMed ID: 34389432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
    Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
    Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depleting hsa_circ_0000567 suppresses acquired gefitinib resistance and proliferation of lung adenocarcinoma cells through regulating the miR-377-3p / ZFX axis: an in vitro and in vivo study.
    Wang L; Li M; Lian R
    Histol Histopathol; 2022 Jul; 37(7):637-654. PubMed ID: 35133000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells.
    Liu S; Jiang Z; Xiao P; Li X; Chen Y; Tang H; Chai Y; Liu Y; Zhu Z; Xie Q; He W; Ma Y; Jin L; Feng W
    Cancer Sci; 2022 Jan; 113(1):79-90. PubMed ID: 34706132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyphyllin I ameliorates gefitinib resistance and inhibits the VEGF/VEGFR2/p38 pathway by targeting HIF-1a in lung adenocarcinoma.
    Zhang D; Tian X; Wang Y; Liu F; Zhang J; Wang H; Zhang N; Yan T; Lin C; Shi Z; Liu R; Jiang S
    Phytomedicine; 2024 Jul; 129():155690. PubMed ID: 38761523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Analysis of Circular RNA Expression Profiles in Gefitinib-Resistant Lung Adenocarcinoma Patients.
    Zou J; Lan H; Li W; Xie S; Tong Z; Song X; Wang C
    Technol Cancer Res Treat; 2022; 21():15330338221139167. PubMed ID: 36537128
    [No Abstract]   [Full Text] [Related]  

  • 8. Lentivirus-mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro.
    Li YQ; Liu YS; Ying XW; Zhou HB; Wang Z; Wu SC; Yan JP; Jing YT; Yang Y
    Biotechnol Prog; 2018 Jan; 34(1):196-205. PubMed ID: 28960861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m
    Lin X; Ye R; Li Z; Zhang B; Huang Y; Du J; Wang B; Meng H; Xian H; Yang X; Zhang X; Zhong Y; Huang Z
    Drug Resist Updat; 2023 Jan; 66():100908. PubMed ID: 36493511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).
    Lou L; Wang J; Lv F; Wang G; Li Y; Xing L; Shen H; Zhang X
    Cell Oncol (Dordr); 2021 Feb; 44(1):109-133. PubMed ID: 32894437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-Methionine accentuates anti-tumor action of Gefitinib in Gefitinib-resistant lung adenocarcinoma: Role of EGFR/ERK/AKT signaling and histone H3K36me2 alteration.
    Pal S; Kabeer SW; Tikoo K
    Toxicol Appl Pharmacol; 2024 Apr; 485():116907. PubMed ID: 38521369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIF-1α-HPRT1 axis promotes tumorigenesis and gefitinib resistance by enhancing purine metabolism in EGFR-mutant lung adenocarcinoma.
    Geng P; Ye F; Dou P; Hu C; He J; Zhao J; Li Q; Bao M; Li X; Liu X; Xu G
    J Exp Clin Cancer Res; 2024 Sep; 43(1):269. PubMed ID: 39343971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
    Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
    Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
    Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
    J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance.
    Dai C; Liu B; Li S; Hong Y; Si J; Xiong Y; Wu N; Ma Y
    Technol Cancer Res Treat; 2021; 20():15330338211056809. PubMed ID: 34825849
    [No Abstract]   [Full Text] [Related]  

  • 17. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
    Tohmé R; Izadmehr S; Gandhe S; Tabaro G; Vallabhaneni S; Thomas A; Vasireddi N; Dhawan NS; Ma'ayan A; Sharma N; Galsky MD; Ohlmeyer M; Sangodkar J; Narla G
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. METTL1/FOXM1 promotes lung adenocarcinoma progression and gefitinib resistance by inhibiting PTPN13 expression.
    Peng W; Fu J; Zhou L; Duan H
    Cancer Med; 2024 Jul; 13(13):e7420. PubMed ID: 38967523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
    Huang L; Hou M; Liu J; Li Y; Shen W; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):771-781. PubMed ID: 36419390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daidzein Synergizes with Gefitinib to Induce ROS/JNK/c-Jun Activation and Inhibit EGFR-STAT/AKT/ERK Pathways to enhance Lung Adenocarcinoma cells chemosensitivity.
    Mhone TG; Chen MC; Kuo CH; Shih TC; Yeh CM; Wang TF; Chen RJ; Chang YC; Kuo WW; Huang CY
    Int J Biol Sci; 2022; 18(9):3636-3652. PubMed ID: 35813479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.